PepMix™ Peptide Pools

Applications for PepMix™ Peptide Pools

• Antigen specific immunostimulation of T-lymphocytes
• Monitoring of immune status during diseases or therapy
• Assessment of vaccine efficacy
• T-cell expansion
• Cellular immune response profiling
• Identification of the best antigen for individual patients (PepMix™ Collections)
  
  Application Notes:
  

  
  Download our Application Note on CMV PepMixes™:
  "Cytomegalovirus protein spanning PepMix™ peptide pools to discover changes in T cell immunity in the aging population"
  by F. Kern, Brighton and Sussex Medical School, UK
  
  Download our Application Note on PepMixes™ Peptide Pools for Clinical Applications:
  "T cell therapy for viral infections after hematopoietic stem cell transplant"
  by A. M. Leen, Baylor College of Medicine TX, USA
  
  Download our Application Note on Peptide library and pool qualification for clinical trials:
  "Qualification and use of peptide libraries for clinical trial immunomonitoring"
  by Josephine H Cox & Peter Hayes, The International AIDS Vaccine Initiative, London, GB
  

Benefits of PepMix™ Peptide Pools

Peptide pools are preferable to whole proteins for T cell stimulation because:

• Equivalent or better stimulation of CD4 and CD8 cells with peptides
• More reliable as control than phytohemagglutinin (PHA) and concanavalin A (ConA)
• Improved responses in stored blood and PBM cells with peptides
• High-batch-to-batch reproducibility
• Reliable chemical and biochemical quality control and quality assurance are applicable for peptide synthesis and peptide pool generation
• Prolonged shelf stability when stored freeze dried
  
  

Testimonials for PepMix™ Peptide Pools

"I have used JPT's peptide pools (PepMix™) for years now, with great satisfaction! First CMV derived peptides and now also EBV. So far we have published data in one publication and plan several more in the near future."
Anna Karin Lidehaell (Uppsala University, Clin. Immunol., Uppsala, Sweden)

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

More testimonials under JPT Testimonials

Selected References for PepMix™ Peptide Pools:

Control Pools:
Polyfunctional T Cells Accumulate in Large Human Cytomegalovirus-Specific T Cell Responses
Lachmann et al., J. Virol. (2012)
Generation of a Multipathogen-Specific T-cell Product for Adoptive Immunotherapy Based on Activation-Dependent Expression of CD154
Khanna et al., Blood (2011)
AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
Malmström et al., Clin. Cancer Res. (2010)

Infectious Diseases:
An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
Skoberne et al., J. Virol. (2013)
Distinct Gene-expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
Hu et al., Blood. (2013)
T-cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
Secondino et al., Ann. Onc. (2012)
Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
Hoft et al., The Journal of Infectious Disease (2011)
Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV
Mellberg et al., AIDS Research and Therapy (2011)
Polyomavirus BK Large T-antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell Response
Ramaswami et al., Clin. Vaccine Immunol (2011)

Tumor Associated Antigens:
Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
Gerdemann et al., Molecular Therapy (2011)
Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Cruz et al., Clin. Cancer Res. (2011)
Prophylactic Transfer of BCR-ABL–, PR1-, and WT1-Reactive Donor T Cells after T cell–Depleted Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Myeloid Leukemia
Bornhäuser et al., Blood. (2011)
Induction of Complete and Molecular Remissions in Acute Myeloid Leukemia by Wilms’ Tumor 1 Antigen-Targeted Dendritic Cell Vaccination
Tendeloo et al., PNAS (2010)
High-Avidity Cytotoxic-T-lymphocytes Specific for a New Preferentially Expressed antigen of Melanoma (PRAME)-Derived Peptide can Target Leukemic- and Leukemic-precursor Cells
Quintarelli et al. Blood (2010)

More references under JPT Publications/Literature